Literature DB >> 21668310

Epitope spreading contributes to effective immunotherapy in metastatic melanoma patients.

Nicola Hardwick1, Benjamin Chain.   

Abstract

In recent years, there have been reports of immunotherapy inducing objective clinical responses in limited numbers of cancer patients. More frequently, however, clinical responses are not observed. Understanding the immunological mechanisms underlying successful immunotherapy are crucial if the field is to move forward. In the article under evaluation, Coulie et al. examine the T-cell receptor repertoire in a melanoma patient showing durable remission after MAGE-specific immunotherapy. The paper provides convincing evidence that the phenomenon of epitope spreading is critical to the development of effective antitumor immunity.

Entities:  

Year:  2011        PMID: 21668310     DOI: 10.2217/imt.11.62

Source DB:  PubMed          Journal:  Immunotherapy        ISSN: 1750-743X            Impact factor:   4.196


  13 in total

1.  Therapeutic vaccines: the ultimate personalized therapy?

Authors:  James L Gulley
Journal:  Hum Vaccin Immunother       Date:  2012-09-20       Impact factor: 3.452

2.  Mucosal HPV E6/E7 Peptide Vaccination in Combination with Immune Checkpoint Modulation Induces Regression of HPV+ Oral Cancers.

Authors:  Stephanie Dorta-Estremera; Renee L Chin; Gloria Sierra; Courtney Nicholas; Ananta V Yanamandra; Sita M K Nookala; Guojun Yang; Shail Singh; Michael A Curran; K Jagannadha Sastry
Journal:  Cancer Res       Date:  2018-07-27       Impact factor: 12.701

Review 3.  Animal models for IgE-meditated cancer immunotherapy.

Authors:  Tracy R Daniels; Otoniel Martínez-Maza; Manuel L Penichet
Journal:  Cancer Immunol Immunother       Date:  2011-12-23       Impact factor: 6.968

4.  Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer.

Authors:  James L Gulley; Ravi A Madan; Kwong Y Tsang; Caroline Jochems; Jennifer L Marté; Benedetto Farsaci; Jo A Tucker; James W Hodge; David J Liewehr; Seth M Steinberg; Christopher R Heery; Jeffrey Schlom
Journal:  Cancer Immunol Res       Date:  2013-11-04       Impact factor: 11.151

Review 5.  Integrating Immunotherapies in Prostate Cancer.

Authors:  Julius Strauss; Ravi A Madan
Journal:  Curr Oncol Rep       Date:  2015-10       Impact factor: 5.945

Review 6.  Trial Watch: Peptide-based anticancer vaccines.

Authors:  Jonathan Pol; Norma Bloy; Aitziber Buqué; Alexander Eggermont; Isabelle Cremer; Catherine Sautès-Fridman; Jérôme Galon; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2015-01-09       Impact factor: 8.110

Review 7.  Classification of current anticancer immunotherapies.

Authors:  Lorenzo Galluzzi; Erika Vacchelli; José-Manuel Bravo-San Pedro; Aitziber Buqué; Laura Senovilla; Elisa Elena Baracco; Norma Bloy; Francesca Castoldi; Jean-Pierre Abastado; Patrizia Agostinis; Ron N Apte; Fernando Aranda; Maha Ayyoub; Philipp Beckhove; Jean-Yves Blay; Laura Bracci; Anne Caignard; Chiara Castelli; Federica Cavallo; Estaban Celis; Vincenzo Cerundolo; Aled Clayton; Mario P Colombo; Lisa Coussens; Madhav V Dhodapkar; Alexander M Eggermont; Douglas T Fearon; Wolf H Fridman; Jitka Fučíková; Dmitry I Gabrilovich; Jérôme Galon; Abhishek Garg; François Ghiringhelli; Giuseppe Giaccone; Eli Gilboa; Sacha Gnjatic; Axel Hoos; Anne Hosmalin; Dirk Jäger; Pawel Kalinski; Klas Kärre; Oliver Kepp; Rolf Kiessling; John M Kirkwood; Eva Klein; Alexander Knuth; Claire E Lewis; Roland Liblau; Michael T Lotze; Enrico Lugli; Jean-Pierre Mach; Fabrizio Mattei; Domenico Mavilio; Ignacio Melero; Cornelis J Melief; Elizabeth A Mittendorf; Lorenzo Moretta; Adekunke Odunsi; Hideho Okada; Anna Karolina Palucka; Marcus E Peter; Kenneth J Pienta; Angel Porgador; George C Prendergast; Gabriel A Rabinovich; Nicholas P Restifo; Naiyer Rizvi; Catherine Sautès-Fridman; Hans Schreiber; Barbara Seliger; Hiroshi Shiku; Bruno Silva-Santos; Mark J Smyth; Daniel E Speiser; Radek Spisek; Pramod K Srivastava; James E Talmadge; Eric Tartour; Sjoerd H Van Der Burg; Benoît J Van Den Eynde; Richard Vile; Hermann Wagner; Jeffrey S Weber; Theresa L Whiteside; Jedd D Wolchok; Laurence Zitvogel; Weiping Zou; Guido Kroemer
Journal:  Oncotarget       Date:  2014-12-30

Review 8.  Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment.

Authors:  James L Gulley; Ravi A Madan; Russell Pachynski; Peter Mulders; Nadeem A Sheikh; James Trager; Charles G Drake
Journal:  J Natl Cancer Inst       Date:  2017-04-01       Impact factor: 13.506

9.  Combination of novel intravesical xenogeneic urothelial cell immunotherapy and chemotherapy enhances anti-tumor efficacy in preclinical murine bladder tumor models.

Authors:  Chi-Ping Huang; Chun-Chie Wu; Chih-Rong Shyr
Journal:  Cancer Immunol Immunother       Date:  2020-11-06       Impact factor: 6.968

Review 10.  Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications.

Authors:  B Harpreet Singh; James L Gulley
Journal:  Asian J Androl       Date:  2014 May-Jun       Impact factor: 3.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.